Twelve years experience with etanercept in the treatment of rheumatoid arthritis: How it has changed clinical practice

Fabiola Atzeni, Piercarlo Sarzi-Puttini

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.

Original languageEnglish
Pages (from-to)213-222
Number of pages10
JournalExpert Review of Clinical Immunology
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Rheumatoid Arthritis
Clinical Trials
Psoriatic Arthritis
Juvenile Arthritis
Ankylosing Spondylitis
Therapeutics
Psoriasis
Methotrexate
Signs and Symptoms
Arthritis
Observational Studies
Lymphoma
Randomized Controlled Trials
Quality of Life
Etanercept
Incidence
Infection
Pharmaceutical Preparations
Population
Neoplasms

Keywords

  • adverse events
  • clinical efficacy
  • etanercept
  • pharmacokinetics
  • safety
  • trials

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Twelve years experience with etanercept in the treatment of rheumatoid arthritis : How it has changed clinical practice. / Atzeni, Fabiola; Sarzi-Puttini, Piercarlo.

In: Expert Review of Clinical Immunology, Vol. 8, No. 3, 03.2012, p. 213-222.

Research output: Contribution to journalArticle

@article{ed85be931e5744038698aa09d3f121e4,
title = "Twelve years experience with etanercept in the treatment of rheumatoid arthritis: How it has changed clinical practice",
abstract = "Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.",
keywords = "adverse events, clinical efficacy, etanercept, pharmacokinetics, safety, trials",
author = "Fabiola Atzeni and Piercarlo Sarzi-Puttini",
year = "2012",
month = "3",
doi = "10.1586/eci.12.6",
language = "English",
volume = "8",
pages = "213--222",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Twelve years experience with etanercept in the treatment of rheumatoid arthritis

T2 - How it has changed clinical practice

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

PY - 2012/3

Y1 - 2012/3

N2 - Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.

AB - Etanercept is approved for the treatment of patients with moderate-to-severe active rheumatoid arthritis (RA), polyarticular juvenile RA, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Randomized clinical trials have shown that it improves the signs and symptoms of early and long-standing RA and other inflammatory arthritides, prevents radiographic progression and improves the patients health-related quality of life. It is more effective when combined with methotrexate than alone. It is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by clinical trials, long-term observational studies and postmarketing surveillance over 12 years use in clinical practice. It slightly increases the risk of serious infections. The incidence of malignancies during clinical trials and postmarketing surveillance is no different from that expected in the general population, except for the greater frequency of lymphoma. However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA.

KW - adverse events

KW - clinical efficacy

KW - etanercept

KW - pharmacokinetics

KW - safety

KW - trials

UR - http://www.scopus.com/inward/record.url?scp=84858409214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858409214&partnerID=8YFLogxK

U2 - 10.1586/eci.12.6

DO - 10.1586/eci.12.6

M3 - Article

C2 - 22390484

AN - SCOPUS:84858409214

VL - 8

SP - 213

EP - 222

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 3

ER -